tumor-induced immunosuppression [1] . Therefore, we hypothesized that G47∆-mIL12, which induces antitumor immune responses, should synergize with immune checkpoint inhibitor (ICI) antibodies in impeding GBM growth. In the 005 model, ICI antibody alone (anti-PD-1 or anti-CTLA-4) produced only modest improvement in survival, similar to virotherapy (G47∆-mIL12) alone, while the combination of G47∆-mIL12 with either antibody or combination of two antibodies further extended survival modestly [3] . The limited efficacy of the dual combination was not due to the inability of antibodies to cross the blood brain/tumor barrier, since antibodies were detected in the tumor. However, the triple combination of G47∆-mIL12+anti-CTLA-4+anti-PD-1 cured 89% mice with 005 tumors and protected them from lethal tumor re-challenge. These findings were reproduced in another aggressive immune competent glioma model, CT-2A [3] . Though single or dual therapies significantly modulated the tumor microenvironment, triple combination therapy produced the most prominent anti-tumor effects, such as a significant reduction in tumor cells, influx of M1-like TAMs, increased proliferating T cells, and an increased T effector/regulatory cell ratio ( Figure 1 ). Depletion studies demonstrated a requirement for CD4 + , CD8 + T cells, and macrophages for therapeutic efficacy, with CD4 + T cells playing an essential role [3] . It remains to be determined which factor/gene(s) were responsible for the complex immune cell interactions and how they contributed to CD4 + T cell-dependent therapeutic benefit. Whether triple therapy using other oncolytic viruses results in similar curative benefits will be important to determine.
An oHSV encoding human granulocyte-macrophage colony-stimulating factor (GM-CSF) (Talimogene laherparepvec or T-VEC), similar to G47∆-mIL12, was recently approved for the treatment of patients with advanced melanoma, an immunogenic tumor [6] . Followon clinical trials with T-VEC in combination with anti-CTLA-4 (ipilimumab) in melanoma elicited significant clinical responses, with a durable response rate of 50% [7] . However, triple combination therapy (oHSV+anti-CTLA4+anti-PD-1) may be required to obtain curative responses in the majority of cancer patients with non-immunogenic or ICI non-responding tumors, as described for GBM [3] .
An important issue to be addressed before the full potential of oHSV-based cancer immunotherapy is Editorial realized is maximizing oHSV replication/spread within the tumor and developing representative preclinical models. For example, oHSV replication is limited in mouse tumors [2] , and anti-viral immune responses can limit virus spread in patients. Therefore, developing strategies to enhance tumor-specific viral replication and spread, and anti-tumor immunity without compromising safety is key for clinical success. More research is needed to optimize new viral vectors and design more rationale combination clinical trials. This may include the generation of new oHSV vectors expressing other immune modulators, testing them in combination with other immunotherapies, and expanding clinical development to patients with minimally immunotherapy responsive lethal cancers, like GBM.
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